R. Pillai

Lower airway dysbiosis affects lung cancer progression.

Richard Bonneau, J. Clemente, G. Michaud, 2020, Cancer discovery.

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance

C. Rudin, Kwok-Kin Wong, A. Moreira, 2021, bioRxiv.

QX-314 Produces Long-lasting Local Anesthesia Modulated by Transient Receptor Potential Vanilloid Receptors in Mice

C. Ries, B. MacLeod, S. Schwarz, 2009, Anesthesiology.

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

C. Rudin, A. Tsirigos, Shih-Ming Huang, 2023, bioRxiv.

Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition

J. Rabinowitz, T. Papagiannakopoulos, Sarah E LeBoeuf, 2021, Science advances.

NRF2: KEAPing Tumors Protected.

M. Hayashi, T. Papagiannakopoulos, Anastasia-Maria Zavitsanou, 2022, Cancer discovery.

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

A. Tsirigos, M. Hayashi, J. Poirier, 2024, Science advances.